Witryna12 kwi 2024 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Impel Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for IMPL. The average twelve-month price prediction for Impel Pharmaceuticals is $21.25 with a high price target of $40.00 and a low price target of … Witryna6 sty 2024 · Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel ...
Impel Pharmaceuticals Company Profile: Stock Performance
WitrynaImpel Pharmaceuticals Inc. is a Seattle-based, commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for disorders with high unmet medical needs. IMPEL, POD, Trudhesa, Trudhesa DIRECT, and the Impel and … Impel Pharmaceuticals’ mission is to create and provide transformative therapies for … Impel Pharmaceuticals has developed a proprietary drug delivery technology … The efficacy of currently approved DHE-based medications is well-established … Impel INP105 – Acute Treatment of Agitation and Aggression in Autism … Impel Pharmaceuticals is currently developing INP107, a non-invasive, self- … impel pharmaceuticals has developed its proprietary Precision Olfactory Delivery … Archive of posts categorized by Publications in Impel Pharmaceuticals. Impel … Impel attended the 2024 Headache Cooperative of the Pacific’s 14th Annual … WitrynaThis presentation and the accompanying oral commentary by Impel NeuroPharma, Inc. (“we,” “us,” “our,” “Impel” or the “Company”) contains forward-looking statements that … simple lace flower girl dress
DATE: April 2024 POSITION: LOCATION: REPORTS TO ... - Impel …
Witryna11 lut 2024 · Impel adopting Veeva software, data, and consulting to accelerate pre-launch planning and digital-first commercial execution. SEATTLE and PLEASANTON, CA — February 10, 2024 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of … Witryna2 cze 2024 · Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product … WitrynaImpel NeuroPharma. Sep 2024 - Present1 year 8 months. Salt Lake City, Utah, United States. Launch of a new migraine product with Impel, I cover the greater SLC territory and north up to Idaho ... rawr pets new plymouth